Canaccord initiated coverage of Tempus AI (TEM) with a Buy rating and $110 price target Tempus offers oncology testing for genomic profiling, data services and artificial intelligence applications, the analyst tells investors in a research note. The firm says the potential of AI deployment at scale in clinical practice could support “strong” long-term revenue growth for Tempus.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade TEMPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI enters pact with Whitehawk Therapeutics to advance oncology research
- Tempus AI selected by ARPA-H to provide CRO services
- tempus AI Inc Class A call volume above normal and directionally bullish
- Tempus AI Stock (TEM) Spikes 9%— Should You Buy Now?
- Ambry Genetics announces improved EHR-integrated BC risk assessment solution